Vertex Pharmaceuticals Inc. closed 5.66% below its 52-week high of $519.88, which the company reached on November 8th.

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 2.92% to $485.89 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to ...

On 30 January 2025, the US Food and Drug Administration (FDA) approved the non-opioid medication suzetrigine (JOURNAVX), which was developed by Vertex Pharmaceuticals for moderate to severe acute ...

In its first quarter 2025 investor letter, GreensKeeper Asset Management emphasized stocks such as Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ...

In its first quarter 2025 investor letter, GreensKeeper Asset Management emphasized stocks such as Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Vertex Pharmaceuticals Incorporated (NASDAQ ...

However, local pharmacists said you should also keep a close eye on your medicine cabinets.That's as President Donald Trump said pharmaceuticals could be next on the tariff list. WDSU Reporter ...

Now that they've become cheaper in the sell-off, it's a great time to buy. Vertex Pharmaceuticals is another leading drugmaker that famously dominates its market: medicines for cystic fibrosis (CF ...

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma Kewalramani, M.D., to $21.5 million, according to the company’s proxy filing.

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about ...